"Mydriasis Treatment Market"Mydriasis Companies are Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others (Albany, USA) DelveInsight's ...

Vindesine (VDS), one of the vinca alkaloids, is widely used as an antineoplastic agent. Possible target sites are microtubules and tubulins in cancer cells. As the adverse effects of VDS, ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis. Ryzumvi is expected to be ...

Please provide your email address to receive an email when new articles are posted on . Significantly more participants treated with phentolamine ophthalmic solution 0.75% vs. placebo achieved ...

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...

Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...

DelveInsight’s ‘Mydriasis Epidemiology Forecast 2030’ report delivers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, ...

Eye drop treatment indicated for pharmacologically induced mydriasis. Viatris Inc. and Ocuphire Pharma, Inc. revealed that the FDA has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the ...

Viatris Inc., a global healthcare company, announced the US commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by ...

In the U.S., an estimated 100 million comprehensive eye exams take place each year that involve pharmacologically-induced mydriasis (or dilation) of the pupils 1, which can last up 24 hours 2. Side ...